药捷安康-B早盘涨近11%创上市新高 公司获纳入港股通名单-港股-金融界

Core Viewpoint - The stock of药捷安康-B (02617) surged over 10% in early trading, reaching a new high of 78 HKD, driven by its inclusion in the Hong Kong Stock Connect program and the progress of its clinical trials for its core product, Tinengotinib [1] Group 1 - The stock price of药捷安康-B increased by 10.54%, trading at 69.75 HKD with a transaction volume of 54.34 million HKD [1] - The company has been added to the Hong Kong Stock Connect eligible list, effective from September 8 [1] - The company announced the completion of the first patient dosing in a Phase II clinical study for its core product Tinengotinib in combination with other therapies for advanced hepatocellular carcinoma [1]